TLSA
Tiziana Life Sciences Ltd
Biotechnology
Market Cap$192M
5Y Perf.-43.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TLSA vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-20.9%
TLSA vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TLSA | RCUS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $192M | $2.50B |
| Revenue (TTM) | $0.00 | $236M |
| Net Income (TTM) | $-34M | $-369M |
| Gross Margin | — | 90.7% |
| Operating Margin | — | -168.6% |
| Total Debt | $106K | $99M |
| Cash & Equiv. | $4M | $222M |
TLSA vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TLSA
RCUS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tiziana Life Scienc… (TLSA) | 100 | 57.0 | -43.0% |
| Arcus Biosciences, … (RCUS) | 100 | 79.1 | -20.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TLSA vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RCUS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Tiziana Life Sciences Ltd is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TLSA
Tiziana Life Sciences Ltd
The Income Pick
TLSA is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.74
- EPS growth 35.3%
- Lower volatility, beta 0.74, Low D/E 2.7%, current ratio 1.02x
Best for: income & stability and growth exposure
RCUS
Arcus Biosciences, Inc.
The Long-Run Compounder
RCUS carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 45.9% 10Y total return vs TLSA's -63.8%
- -4.3% revenue growth vs TLSA's -57.8%
- +209.6% vs TLSA's -3.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RCUS | -4.3% revenue growth vs TLSA's -57.8% |
| Quality / Margins | TLSA | 7.2% margin vs RCUS's -156.4% |
| Stability / Safety | TLSA | Beta 0.74 vs RCUS's 1.95, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RCUS | +209.6% vs TLSA's -3.8% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs TLSA's -303.2%, ROIC -64.1% vs -481.7% |
TLSA vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
TLSA vs RCUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRCUSLAGGINGTLSA
TLSATiziana Life Sciences…
1leads
RCUSArcus Biosciences, In…
3leads
6 Total Categories
CATEGORYLEADERvs TLSAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TLSA1/1
Valuation MetricsMultiples, price ratios, and targets
RCUS2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RCUS6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
RCUS4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TLSA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RCUS and TLSA operate at a comparable scale, with $236M and $0 in trailing revenue.
| Metric | TLSATiziana Life Scie… | RCUSArcus Biosciences… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $236M |
| EBITDAEarnings before interest/tax | -$40M | -$391M |
| Net IncomeAfter-tax profit | -$34M | -$369M |
| Free Cash FlowCash after capex | -$14M | -$489M |
| Gross MarginGross profit ÷ Revenue | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | -168.6% |
| Net MarginNet income ÷ Revenue | — | -156.4% |
| FCF MarginFCF ÷ Revenue | — | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.8% | +10.5% |
TLSA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RCUS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | TLSATiziana Life Scie… | RCUSArcus Biosciences… |
|---|---|---|
| Market CapShares × price | $192M | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $189M | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -6.86x | -7.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 10.11x |
| Price / BookPrice ÷ Book value/share | 20.46x | 4.22x |
| Price / FCFMarket cap ÷ FCF | — | — |
RCUS leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
RCUS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
RCUS delivers a -69.0% return on equity — every $100 of shareholder capital generates $-69 in annual profit, vs $-9 for TLSA. TLSA carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), TLSA scores 2/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | TLSATiziana Life Scie… | RCUSArcus Biosciences… |
|---|---|---|
| ROE (TTM)Return on equity | -8.7% | -69.0% |
| ROA (TTM)Return on assets | -3.0% | -35.3% |
| ROICReturn on invested capital | -4.8% | -64.1% |
| ROCEReturn on capital employed | -3.3% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 0 |
| Debt / EquityFinancial leverage | 0.03x | 0.16x |
| Net DebtTotal debt minus cash | -$4M | -$123M |
| Cash & Equiv.Liquid assets | $4M | $222M |
| Total DebtShort + long-term debt | $106,000 | $99M |
| Interest CoverageEBIT ÷ Interest expense | -2622.00x | -13.38x |
RCUS leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RCUS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $8,143 today (with dividends reinvested), compared to $6,345 for TLSA. Over the past 12 months, RCUS leads with a +209.6% total return vs TLSA's -3.8%. The 3-year compound annual growth rate (CAGR) favors TLSA at 23.6% vs RCUS's 7.7% — a key indicator of consistent wealth creation.
| Metric | TLSATiziana Life Scie… | RCUSArcus Biosciences… |
|---|---|---|
| YTD ReturnYear-to-date | -5.6% | +6.5% |
| 1-Year ReturnPast 12 months | -3.8% | +209.6% |
| 3-Year ReturnCumulative with dividends | +88.7% | +24.9% |
| 5-Year ReturnCumulative with dividends | -36.6% | -18.6% |
| 10-Year ReturnCumulative with dividends | -63.8% | +45.9% |
| CAGR (3Y)Annualised 3-year return | +23.6% | +7.7% |
RCUS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TLSA and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
TLSA is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than RCUS's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 86.3% from its 52-week high vs TLSA's 58.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TLSATiziana Life Scie… | RCUSArcus Biosciences… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 1.95x |
| 52-Week HighHighest price in past year | $2.60 | $28.72 |
| 52-Week LowLowest price in past year | $1.14 | $7.06 |
| % of 52W HighCurrent price vs 52-week peak | +58.1% | +86.3% |
| RSI (14)Momentum oscillator 0–100 | 66.4 | 60.5 |
| Avg Volume (50D)Average daily shares traded | 149K | 1.2M |
Evenly matched — TLSA and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TLSA as "Buy" and RCUS as "Buy".
| Metric | TLSATiziana Life Scie… | RCUSArcus Biosciences… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $30.00 |
| # AnalystsCovering analysts | 3 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCUS leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). TLSA leads in 1 (Income & Cash Flow). 1 tied.
Best OverallArcus Biosciences, Inc. (RCUS)Leads 3 of 6 categories
Loading custom metrics...
TLSA vs RCUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TLSA or RCUS a better buy right now?
Analysts rate Tiziana Life Sciences Ltd (TLSA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TLSA or RCUS?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -18. 6%, compared to -36. 6% for Tiziana Life Sciences Ltd (TLSA). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus TLSA's -63. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TLSA or RCUS?
By beta (market sensitivity over 5 years), Tiziana Life Sciences Ltd (TLSA) is the lower-risk stock at 0.
74β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 165% more volatile than TLSA relative to the S&P 500. On balance sheet safety, Tiziana Life Sciences Ltd (TLSA) carries a lower debt/equity ratio of 3% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TLSA or RCUS?
On earnings-per-share growth, the picture is similar: Tiziana Life Sciences Ltd grew EPS 35.
3% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TLSA or RCUS?
Tiziana Life Sciences Ltd (TLSA) is the more profitable company, earning 0.
0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TLSA leads at 0. 0% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TLSA or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TLSA or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Tiziana Life Sciences Ltd (TLSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
74)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TLSA: -63. 8%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TLSA and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.